Omnicell (OMCL) Expected to Announce Earnings on Tuesday

Omnicell (NASDAQ:OMCL - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Omnicell to post earnings of $0.16 per share and revenue of $260.18 million for the quarter. Omnicell has set its Q1 2025 guidance at 0.150-0.250 EPS and its FY 2025 guidance at 1.650-1.850 EPS.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Trading Down 0.4 %

Omnicell stock opened at $30.84 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The business's fifty day simple moving average is $34.14 and its two-hundred day simple moving average is $40.76. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.75. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 114.23, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wells Fargo & Company dropped their target price on Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. JPMorgan Chase & Co. lowered their price target on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. StockNews.com raised Omnicell from a "hold" rating to a "buy" rating in a report on Friday. Bank of America lowered their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Finally, Benchmark reaffirmed a "buy" rating and set a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $50.67.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.